 |
13 Diseases |  |
2 Trials |
|
2 Trials |  |
18 News |  |
- ||| TOUR006 / Tourmaline Bio
Enrollment open: TRANQUILITY: A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (clinicaltrials.gov) - May 7, 2024
P2, N=120, Recruiting, Sponsor: Tourmaline Bio, Inc.
Not yet recruiting --> Recruiting
- |||| TOUR006 / Tourmaline Bio
New P2 trial: TRANQUILITY: A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (clinicaltrials.gov) - Apr 12, 2024
P2, N=120, Not yet recruiting, Sponsor: Tourmaline Bio, Inc.
- | TOUR006 / Tourmaline Bio
Phase classification: spiriTED: A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease (clinicaltrials.gov) - Nov 30, 2023
P2, N=81, Recruiting, Sponsor: Tourmaline Bio, Inc.
Not yet recruiting --> Recruiting Phase classification: P2b --> P2
- |||| TOUR006 / Tourmaline Bio
New P2 trial, New P2b trial: spiriTED: A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease (clinicaltrials.gov) - Oct 17, 2023
P2b, N=81, Recruiting, Sponsor: Tourmaline Bio, Inc.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, PF-04236921 / Pfizer, Xeljanz (tofacitinib) / Pfizer
Clinical, Retrospective data, Review: Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn's Disease. (Pubmed Central) - Apr 12, 2022
In general, tumor necrosis factor (TNF)-α inhibitors were the most effective biologics, and the highest efficacy of small targeted molecules was observed in janus kinase (JAK) inhibitors. These findings have important implications for clinical practice in CD.
- Stelara (ustekinumab) / J&J, Epratucyn (epratuzumab) / Gilead
[VIRTUAL] Efficacy of Biological Agents for the Management of Systemic Lupus Erythematosus: A Systematic Review and Network Meta-Analysis () - Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_135;
This systematic review identified that there was heterogeneity in the outcome measures and endpoints used. In the future, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach will be applied to rate the quality of the evidence, and to gain insight into methodological pitfalls that could have negatively altered the results of RCTs.
- | PF-04236921 / Pfizer
Clinical, PK/PD data, Journal: Pharmacokinetics and C-Reactive Protein Modelling of Anti-IL-6 Antibody (PF-04236921) in Healthy Volunteers and Patients with Autoimmune Disease. (Pubmed Central) - Oct 16, 2019
Integrated population PK and PK/PD models of PF-04236921 have been developed using pooled data from healthy subjects and autoimmune patients. The current model enables simulation of PF-04236921 PK and PD profiles under various dosing regimens and patient populations and should facilitate future clinical study of PF-04236921 and other anti-IL6 monoclonal antibodies.
- ||||| TOUR006 / Tourmaline Bio
New P2 trial: Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus (clinicaltrials.gov) - Dec 19, 2017
P2, N=183, Completed, Sponsor: Pfizer
- |||| TOUR006 / Tourmaline Bio
Trial completion: ANDANTE II: B0151005 Open-Label Extension Study (clinicaltrials.gov) - Apr 27, 2016
P2, N=191, Completed, Sponsor: Pfizer
The current model enables simulation of PF-04236921 PK and PD profiles under various dosing regimens and patient populations and should facilitate future clinical study of PF-04236921 and other anti-IL6 monoclonal antibodies. Active, not recruiting --> Completed
- ||| TOUR006 / Tourmaline Bio
Enrollment closed: ANDANTE II: B0151005 Open-Label Extension Study (clinicaltrials.gov) - Dec 25, 2015
P2, N=180, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| TOUR006 / Tourmaline Bio
Trial completion: ANDANTE: A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy (clinicaltrials.gov) - Apr 21, 2015
P2, N=250, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| TOUR006 / Tourmaline Bio
Enrollment closed: ANDANTE: A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy (clinicaltrials.gov) - Oct 10, 2014
P2, N=251, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Completed --> Active, not recruiting
- |||| TOUR006 / Tourmaline Bio
Trial completion: ANDANTE: A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy (clinicaltrials.gov) - Oct 4, 2014
P2, N=251, Completed, Sponsor: Pfizer
Completed --> Active, not recruiting Recruiting --> Completed
- |||| TOUR006 / Tourmaline Bio
Trial completion: Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus (clinicaltrials.gov) - Apr 10, 2014
P2, N=183, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- | TOUR006 / Tourmaline Bio
Trial completion: Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 27, 2012
P1, N=41, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed